Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers


This is a phase II single-blinded study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Diabetic Foot Ulcer, compared to standard therapy.

Full Title of Study: “Phase 2 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers: A Randomized, Comparator-controlled, Single-blind, Parallel-group, Multi-center Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: September 2016

Detailed Description

ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Diabetic Foot Ulcer.


  • Biological: ALLO-ASC-DFU
    • Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
  • Other: Standard therapy
    • Standard therapy conducted for patients with diabetic foot ulcer

Arms, Groups and Cohorts

  • Experimental: ALLO-ASC-DFU
    • Allogeneic mesenchymal stem cells
  • Active Comparator: Standard therapy
    • Standard therapy for patients with diabetic foot ulcer

Clinical Trial Outcome Measures

Primary Measures

  • Proportion of re-epithelialization
    • Time Frame: During 8 weeks

Secondary Measures

  • Proportion of re-epithelialization
    • Time Frame: During 12 weeks
  • Time to re-epithelialization
    • Time Frame: During 12 weeks
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability
    • Time Frame: Follow up to 12 weeks

Participating in This Clinical Trial

Inclusion Criteria

1. Subject is between 18 years and 80 years of age.

2. Subject is diagnosed with Type I or Type II diabetes, and had defined as diabetic foot ulcers presence of wound for more than 4 weeks at the screening visit.

3. Ulcer located the foot, and ulcer size is between 1 cm^2 and 25 cm^2.

4. Ulcer extends into the dermis, subcutaneous tissue, tendon or joint capsule (Wagner grade 1 or 2).

5. Ulcer is free of necrotic debris.

6. Subjects had adequate circulation to ulcer as documented by one of the methods below:

  • Palpation of pulses around ulcer using Doppler exam
  • Ankle Brachial index (ABI) values ranging between 0.7 and 1.3, or
  • Transcutaneous Oxygen Pressure (TcPO2) > 30 mmHg.

7. Subject is able to give written informed consent prior to study start and to comply with the study requirements.

Exclusion Criteria

1. Ulcer is of non-diabetic pathophysiology.

2. The ulcer has increased or decreased in size by 30% or more during one week after the screening visit.

3. Subject is Human Immunodeficiency Virus (HIV) positive.

4. Subjects with severe hepatic deficiencies.

5. Subjects with a glycated hemoglobin A1c (HbA1c) level of > 15%.

6. Subject who are allergic or have a hypersensitive reaction to bovine-derived proteins or fibrin glue.

7. Subjects requiring intravenous (IV) antibiotics to treat the index wound infection.

8. Subjects with severe renal deficiencies that is uncontrolled by dialysis

9. Subjects who are pregnant or breast-feeding.

10. Subjects who are unwilling to use an "effective" method of contraception during the study.

11. Current evidence of severe infection including pus drainage from the wound site.

12. Subjects who have a clinically relevant history of alcohol or drugs abuse.

13. Subject's blood sugar is > 450 mg/dL at postprandial.

14. Subjects who are not able to understand the objective of this study or to comply with the study requirements.

15. Subjects who are considered to have a significant disease which can impact the study by the investigator.

16. Subjects who are considered not suitable for the study by the investigator.

17. Subjects who have a history of surgery for malignant tumor within the last five years (except carcinoma in situ).

18. Subjects who are currently or were enrolled in another clinical study within 60 days of screening.

19. Subjects who have undergone wound treatments with cell therapy, dermal substitutes, or other biological therapies within the last 30 days.

20. Subjects who are receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic agents to unstable dosage.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Anterogen Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Seung-Kyu Han, MD. PhD., Principal Investigator, Korea University Guro Hospital
    • Ki-Won Young, MD. PhD., Principal Investigator, Eulji General Hospital
    • Hyun-suk Suh, MD. PhD., Principal Investigator, Asan Medical Center
    • Jin Woo Lee, MD. PhD., Principal Investigator, Severance Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.